GSK Says Shingrix Shortage, Oncology Push Continues
GlaxoSmithKline Q3 Update Notes PARP Promise, Shingrix Demand
GlaxoSmithKline said its increasingly streamlined operations are on a growth trajectory, but that capacity constraints mean demand for its popular shingles vaccine will keep outstripping supply.
